Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heparin disaccharide III-S is a synthetic or semi-synthetic disaccharide derived from the enzymatic digestion of heparan sulfate and heparin. It is a complex carbohydrate with notable anticoagulant and anti-inflammatory properties. This compound is used primarily in research to study protein-protein interactions and enzymatic activity related to glycosaminoglycans. Structurally, it contains two carbohydrate moieties linked together with multiple sulfate groups. Its mechanism of action involves mimicking specific sulfated motifs found in natural heparins that interact with proteins such as antithrombin III and platelet factor 4 (PF4), which are central to coagulation pathways[1][2][4][7]. Heparin disaccharide III-S itself is not approved for clinical use but serves as an important tool for dissecting structure-function relationships in anticoagulant drug development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin disaccharide iii-s.